Start Date: Sep 01, 2012
End Date: Aug 31, 2015
This is an ancillary study to a randomized clinical trial of Delta Health Alliance (DHA) supplementation in overweight pregnant women. In the clinical trial, overweight pregnant women from Woman’s Hospital in Baton Rouge, LA, will be recruited, consented, and assessed at baseline (17-20 weeks gestation) for biochemical, anthropometric, dietary, and pre-pregnancy health and weight status. Participants will be randomized to DHA supplementation or olive oil placebo for the remainder of their pregnancy. Biochemical and dietary assessments will be repeated at 24, 30, and 36 months gestation and at delivery (no dietary assessment at this data collection point). Venous cord blood will be collected at delivery to determine infant biochemical parameters. Additionally, infant weight, gestational age, and Activity, Pulse, Grimace, Appearance, and Respiration (APGAR) score will be assessed at delivery. Using existing samples from the clinical trial, the iron ancillary study will assess iron status (hemoglobin, ferritin, soluble transferrin receptor, and calculated total body iron), plasma hepcidin, erythropoietin, as well as dietary iron intake at baseline (17-20 weeks gestation), 24, 30 and 36 months gestation and at delivery (no dietary assessment). The ancillary study will also utilize maternal inflammatory, dietary, and anthropometric assessments collected as part of the clinical trial to assess treatment group outcomes. From existing venous cord blood samples collected in the clinical trial (dependent on availability), neonatal iron status (hemoglobin, ferritin, soluble transferrin receptor and calculated total body iron), hepcidin, and erythropoietin will be assessed. The ancillary study will also utilize infant inflammatory markers (IL-6 and CRP), gestational age, APGAR score, mode of delivery, birth weight collected in the clinical trial to compare treatment group outcomes.